Non-small cell lung cancer (NSCLC) with PDL1 expression ≥50% which does not achieve tumour clearance with anti-PD1 treatment research hub

NEOVACC: A personalised DNA vaccine for patients with advanced lung cancer

This study is testing a new, personalised vaccine for advanced lung cancer (NSCLC) that hasn't fully responded to standard treatment. It aims to train your immune system to fight the cancer, used alongside an existing drug called pembrolizumab.